autoimmune drugs
Evommune Files for IPO to Fund Phase 2 Trials of Autoimmune Drug Candidates
Evommune; IPO; Phase 2 trials; autoimmune drugs; EVO756; EVO301; chronic inflammatory diseases; biotech funding; New York Stock Exchange; Series C financing